A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Preliminary Data from AAA-SHAPE to be Presented at VEITHsymposium In New York City

Shape Memory Medical Inc., developer of custom, proprietary shape memory polymers for the peripheral vascular and neurovascular markets, announced preliminary six-month results from the AAA-SHAPE Safety Trial. Data will be presented during the 49th Annual VEITH Symposium in New York City on Tuesday, November 15, 2022.

AAA-SHAPE is the Company’s prospective, multicenter early feasibility safety study of the IMPEDE-FX RapidFill® Device when used for abdominal aortic aneurysm (AAA) sac management during elective endovascular aneurysm repair (EVAR). The trial enrolled a combined 35 patients across two centers in New Zealand and in three centers in the Netherlands, and patients will be followed for two years.

The data will be presented by Professor Michel Reijnen, MD, PhD, vascular surgeon at Rijnstate Hospital in Arnhem, the Netherlands and principal investigator for AAA-SHAPE Netherlands. “Active sac management may become an important addition to EVAR to improve the rate of sac shrinkage,” said Reijnen. “Approximately 40% of AAA patients undergoing EVAR experience sac shrinkage within one year, meaning that the remaining patients either show no improvement in aneurysm size or go on to experience sac growth with a poor prognosis. Adjunctive aneurysm sac filling with shape memory polymer at the time of EVAR has the potential to improve sac regression.”

AAA-SHAPE is the first prospective clinical trial to evaluate the application of shape memory polymer in AAA patients and its potential to remodel the AAA sac and improve aneurysm sac regression following EVAR. IMPEDE-FX RapidFill, the study device, incorporates the novel, high volume, porous embolic material which self-expands upon contact with blood for rapid conversion to organized thrombus. Pre-clinical studies have shown that shape memory polymer is regenerative, activating the formation of new cellular growth as the thrombus remodels and the material is absorbed.

“Treating the AAA sac during EVAR with the IMPEDE-FX RapidFill device could fundamentally change how we treat this disease state,” explained Prof. Andrew Holden, MBChB, principal investigator for AAA-SHAPE New Zealand and interventional radiologist at Auckland City Hospital. “Although contrary to recent thinking, a stable aneurysm following EVAR is no longer sufficient, and seeing sac regression should be the first way to measure treatment success. Early observations from AAA-SHAPE are encouraging, and further follow-up and larger studies are needed to evaluate durability of outcomes.”

Complete cohort data is expected at the end of 2023.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy